RNXT · RenovoRx Inc. Common Stock
View on chartInsiders & Stakes
| Ramtin Agah Chief Medical Officer | ▲ Buy | Open Market | 798,460 Shares held | 1/21/2026 | View profile |
| Shaun Bagai Chief Executive Officer | ▲ Buy | Open Market | 313,357 Shares held | 3/20/2026 | View profile |
| Mark Voll Chief Financial Officer | ▲ Buy | Grant | 222,380 Shares held | 9/10/2026 | View profile |
| Una S. Ryan Director | ▼ Sell | Other | 97,165 Shares held | 4/22/2022 | View profile |
| Robert J. Spiegel Director | ▲ Buy | Open Market | 40,983 Shares held | 1/26/2024 | View profile |
| Macfarlane K. Angela Director | ▲ Buy | Open Market | 40,983 Shares held | 1/26/2024 | View profile |
| Ron Kocak VP Controller and PAO | ▲ Buy | Open Market | 12,595 Shares held | 4/10/2025 | View profile |
| Laurence Marton Director | ▲ Buy | Open Market | 9,720 Shares held | 3/20/2026 | View profile |
| Nelms Angela Chief Operating Officer | ▲ Buy | Open Market | 1,100 Shares held | 10/3/2023 | View profile |
Transaction History
| Mark Voll | ▲ Buy | Grant | 80,000 | $0 | 9/10/2026 |
| Mark Voll | ▲ Buy | Open Market | 25,000 | $20K | 5/19/2026 |
| Mark Voll | ▲ Buy | Grant | 80,000 | $0 | 4/3/2026 |
| Mark Voll | ▲ Buy | Grant | 12,380 | $0 | 3/25/2026 |
| Laurence Marton | ▲ Buy | Open Market | 9,720 | — | 3/20/2026 |
| Shaun Bagai | ▲ Buy | Open Market | 24,300 | — | 3/20/2026 |
| Mark Voll | ▲ Buy | Open Market | 97,200 | — | 3/20/2026 |
| Ramtin Agah | ▲ Buy | Open Market | 10,000 | $10K | 1/21/2026 |
| Ramtin Agah | ▲ Buy | Open Market | 9,795 | $8K | 12/31/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 205 | $169 | 12/30/2025 |
| Shaun Bagai | ▲ Buy | Open Market | 5,000 | $5K | 12/18/2025 |
| Shaun Bagai | ▲ Buy | Open Market | 5,000 | $4K | 12/17/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 12,000 | $10K | 12/16/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 10,000 | $10K | 12/5/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 12,000 | $10K | 11/24/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 10,000 | $8K | 11/21/2025 |
| Shaun Bagai | ▲ Buy | Open Market | 5,000 | $5K | 8/25/2025 |
| Shaun Bagai | ▲ Buy | Open Market | 5,000 | $5K | 8/22/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 21,000 | $29K | 6/5/2025 |
| Laurence Marton | ▲ Buy | Option Exercise | 20,480 | $3K | 5/2/2025 |
| Ramtin Agah | ▼ Sell | Gift | 400,000 | $0 | 4/22/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 15,000 | $14K | 4/15/2025 |
| Shaun Bagai | ▲ Buy | Open Market | 7,500 | $7K | 4/15/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 20,000 | $16K | 4/11/2025 |
| Ron Kocak | ▲ Buy | Open Market | 6,500 | $5K | 4/10/2025 |
| Ron Kocak | ▲ Buy | Open Market | 6,000 | $5K | 4/9/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 30,000 | $24K | 4/9/2025 |
| Shaun Bagai | ▲ Buy | Open Market | 10,000 | $8K | 4/9/2025 |
| Ramtin Agah | ▲ Buy | Open Market | 26,000 | $22K | 4/8/2025 |
| Laurence Marton | ▲ Buy | Open Market | 12,050 | $10K | 4/8/2025 |
| Ron Kocak | ▲ Buy | Open Market | 95 | $76 | 4/8/2025 |
| Shaun Bagai | ▲ Buy | Open Market | 10,000 | $8K | 4/7/2025 |
| Laurence Marton | ▲ Buy | Open Market | 8,196 | — | 1/26/2024 |
| Shaun Bagai | ▲ Buy | Open Market | 40,983 | — | 1/26/2024 |
| Ramtin Agah | ▲ Buy | Open Market | 40,983 | — | 1/26/2024 |
| Macfarlane K. Angela | ▲ Buy | Open Market | 40,983 | — | 1/26/2024 |
| Robert J. Spiegel | ▲ Buy | Open Market | 40,983 | — | 1/26/2024 |
| Nelms Angela | ▲ Buy | Open Market | 800 | $836 | 10/3/2023 |
| Nelms Angela | ▲ Buy | Open Market | 300 | $315 | 10/3/2023 |
| Laurence Marton | ▲ Buy | Option Exercise | 25,438 | $43K | 11/3/2022 |
| Ramtin Agah | ▲ Buy | Open Market | 5,182 | $10K | 6/7/2022 |
| Shaun Bagai | ▲ Buy | Open Market | 5,500 | $11K | 5/19/2022 |
| Una S. Ryan | ▼ Sell | Other | 26,838 | $25K | 4/22/2022 |
| Una S. Ryan | ▼ Sell | Other | 16,206 | $26K | 4/22/2022 |
| Ramtin Agah | ▼ Sell | Gift | 975,000 | $0 | 3/16/2022 |
| Ramtin Agah | ▼ Sell | Gift | 975,000 | $0 | 3/16/2022 |
| Una S. Ryan | ▼ Sell | Other | 6,332 | $25K | 3/3/2022 |
| Una S. Ryan | ▼ Sell | Other | 47,789 | $200K | 3/3/2022 |
| Ramtin Agah | ▼ Sell | Other | 1,295 | — | 8/30/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
RenovoRx publishes peer-reviewed case series in oncology journal
RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.
RenovoRx publishes peer-reviewed case series in oncology journal. RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.